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Condensation: 
The recurrence rates of hypertensive disorders of pregnancy, preeclampsia, 
gestational hypertension, and HELLP syndrome were 20.7%, 13.8%, 8.6%, and 0.2% 
respectively. 
 
Short version of title: 
Individual participant data meta-analysis on the recurrence of hypertensive disorders 
of pregnancy  
 
 
This research was presented as a poster at the 19th Annual Scientific Meeting of the 
International Society for the Study of Hypertension in Pregnancy, ISSHP, New 
Orleans, Louisiana, USA, October 26-29 2014.   
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ABSTRACT: 
 
Objective 
We performed an Individual Participant Data (IPD) meta-analysis to calculate the 
recurrence risk of hypertensive disorders of pregnancy (HDP) and recurrence of 
individual hypertensive syndromes. 
 
Study design 
We performed an electronic literature search for cohort studies that reported on 
women suffering from HDP and who had a subsequent pregnancy. The principal 
investigators were contacted, informed and requested for their original study data. 
The obtained data were merged to form one combined database. The results will be 
presented as % with 95% confidence interval (CI) and odds ratios (OR) with 95% CI. 
 
Results 
Out of 94 eligible cohort studies, we obtained IPD of 22 studies, including a total of 
99,415 women. Pooled data of 64 studies using published data (IPD where available) 
showed a recurrence rate of 18.1% (N=152,213, 95% CI: 17.9 – 18.3). In the 22 
studies included in our IPD, the recurrence rate of a HDP was 20.7% (95%CI: 20.4 – 
20.9). Recurrence manifested as preeclampsia (PE) in 13.8% (95%CI: 13.6 – 14.1), 
gestational hypertension (GH) in 8.6% (95%CI: 8.4 – 8.8) and Hemolysis, Elevated 
Liver enzymes and Low Platelets (HELLP) syndrome in 0.2% (95%CI: 0.16 – 0.25). 
The delivery of a small for gestational age (SGA) child accompanied the recurrent 
HDP in 3.4% (95%CI: 3.2 – 3.6). Concomitant HELLP syndrome or delivery of a SGA 
child increased the risk of recurrence of HDP. Recurrence increased with decreasing 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
4 
 
gestational age at delivery in the index pregnancy. If the HDP recurred, it was in 
general milder, regarding maximum diastolic blood pressure, proteinuria, use of oral 
antihypertensive and anticonvulsive medication, delivery of a SGA child, premature 
delivery and perinatal mortality. Normotensive women developed chronic 
hypertension after pregnancy more often after experiencing recurrence (OR 3.7 95% 
CI: 2.3 – 6.1).  
 
Conclusion 
Among women that suffer hypertension in pregnancy, the recurrence rate in a next 
pregnancy is relatively low and the course of disease is milder for most women with 
recurrent disease. These reassuring data should be used for shared decision making 
in women who consider a new pregnancy after a pregnancy complicated by 
hypertension. 
 
Key words 
Gestational hypertension, HELLP syndrome, IPD, preeclampsia, pregnancy, 
recurrence  
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INTRODUCTION: 
 
Hypertensive disorders of pregnancy (HDP) are a common health problem and are 
the second most common cause of maternal death worldwide, with major intriguing 
regional differences worldwide (1). They complicate approximately 2 to 8 per cent of 
all pregnancies (2,3,4) and comprise gestational hypertension (GH), preeclampsia 
(PE), superimposed PE and HELLP (Hemolysis, Elevated Liver enzymes and Low 
Platelets) syndrome, and in a varying percentage of cases they are related to 
intrauterine growth restriction. There is probably important heterogeneity in 
pathophysiology and clinical phenotype between subgroups and individual women, 
with maternal endothelial dysfunction as a central phenomenon, caused by an 
excessive maternal response to placental material. Furthermore a HDP identifies the 
woman at risk for cardiovascular disease later in life, probably due to shared risk 
factors and pathophysiology (2,4).  
 
Hypertensive disorders of pregnancy can also have a major psychological impact on 
the woman and her family (5) As such, counseling on recurrence of a hypertensive 
disease in a future pregnancy is important. Consequently, many studies focused on 
the investigation of recurrence rates of HDP. Interpretation of these studies, however, 
is difficult because of many potential sources of bias, including patient selection and 
study methodologies. This causes every cohort to have a specific case mix of 
different clinical phenotypes and macro-ethnicities. Reported recurrence rates range 
from a few percent, up to 65% (6). Similarly, the performance of individualized risk 
prediction models has been disappointing, since hypertensive disorders of pregnancy 
have heterogeneous pathophysiology (7). In addition, suboptimal size and 
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generalizability of studies cause these prediction models to be unsatisfactory (7). 
Recurrence rates of the individual syndromes of HDP in literature for preeclampsia 
can be found ranging up to 65% (6) and for HELLP syndrome: 2 – 3% (8,9). 
Recurrence of GH has not been explored in many studies. Delivering a small for 
gestational age (SGA) child recurs in about 24 percent of pregnancies (10). 
 
Individual Participant Data (IPD) meta-analysis is new to prognostic research (11). In 
contrast to conventional meta-analysis it uses the IPD of the original studies, thus 
enlarging the study population and increasing statistical power to detect subtle 
relationships. In contrast to aggregated data meta-analysis, it permits synthesis at an 
individual level, creating flexibility in choosing outcome and subgroups. Additionally, it 
allows redefinition of outcomes or predictors based on continuous variables and 
usage of information that did not reach publication in the original research.  
 
Objective of the study: 
The primary goal of this IPD meta-analysis study is to calculate the recurrence risk of 
hypertensive disorders of pregnancy. Secondarily, we aim to show the recurrence of 
individual hypertensive syndromes.  
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MATERIALS AND METHODS 
 
Sources 
We performed a literature search in the electronic libraries PubMed (Medline) and 
Embase. Language restrictions or restrictions on publication date were not applied. 
The search covered all records until August 2012. The following terms were used: 
‘‘preeclampsia’’ [MeSH] AND [early OR severe OR pre-term OR early onset OR 32 
OR 34 OR 37] AND [history OR previous OR secondary OR subsequent OR 
recurrence]. Cross-references of the selected studies were checked to identify other 
studies of interest. All studies that described cohorts of women with a history of a 
hypertensive disorder that resulted in a delivery at any gestational age were eligible 
for inclusion. Inclusion was not restricted to any study design, apart from for case-
control studies, where recurrence was a prerequisite. Studies that did not report 
recurrence of preeclampsia in the publication, but reasoned to have this information 
in the original data, were also considered eligible. If data between studies 
overlapped, only the larger of the two studies was included. Two independent 
reviewers (M.F.vO. and J.L.) screened the identified articles for eligibility based on 
title and abstract. Discrepancies were resolved by a third reviewer (W.G.). 
 
Data collection 
For each of the eligible articles, contact information of the first, second or last author 
was obtained through Medline, Embase or the internet. We approached the authors 
by email to inform them about the IPD meta-analysis project and to invite them to 
share their data. If authors were willing to participate, they were provided a more 
detailed study proposal, and asked to send their original database. Variables and 
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categories needed to be adequately labeled within the original database or in a 
separate data dictionary. Data of women who had a subsequent pregnancy after the 
hypertensive pregnancy were included. We focused on collecting demographic 
characteristics such as age and Body Mass Index (BMI), cardiovascular risk factors 
and the clinical syndrome of the index pregnancy. The quality of all included studies 
was evaluated with the Newcastle Ottawa Scale for cohort studies (12).  
 
Definitions:  
Hypertensive disorders of pregnancy were defined as gestational hypertension 
(GH), preeclampsia (PE), superimposed PE or HELLP syndrome. Non-hypertensive 
pregnancies with a small for gestational age child (SGA) were excluded. Chronic 
hypertension was not an exclusion criterion for the IPD, but was in some individual 
studies.  
Preeclampsia was defined as hypertension (diastolic blood pressure ≥90 mmHg or 
systolic blood pressure ≥140 mmHg on two occasions, 4-5 hours apart) in 
combination with proteinuria (defined as a positive (0.3 g/l) proteinuria dipstick test, a 
protein/creatinine ratio of 30 mg/mmol or more in a random sample or an urine 
protein excretion of 300 mg or more per 24 hrs.) after 20 weeks of pregnancy (13). 
Mild or severe PE were not separately defined, as only some of the studies made this 
distinction in their data. Women with hypertension beyond 20 weeks without 
proteinuria, or a significant rise in blood pressure if known chronic hypertension, were 
considered to have GH. Chronic hypertension was defined as the presence or history 
of preconceptional hypertension or detection of hypertension in the first half of 
pregnancy. De novo proteinuria or a sudden increase in proteinuria if already 
present, qualified women with chronic hypertension for superimposed preeclampsia 
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(13). HELLP syndrome was defined by hemolysis (elevated lactate dehydrogenase 
(LDH) levels ( ≥ 600 U/L), elevated liver enzymes by levels of aspartate transaminase 
(ASAT) or alanine transferase (ALAT) ≥ 70 U/L and low platelets < 100,000/mm (14). 
HELLP syndrome in combination with hypertension was also classified as PE. SGA 
was defined as birth weight below the 10th percentile, according to the ACOG 
practice bulletin (15) and adjusted for gestational age based on a local reference 
population. The exact definitions for the hypertensive syndromes used in the included 
studies were not retrievable for a few studies, that were published as abstracts 
(20,22). Nevertheless we presume that the authors concur to the international 
accepted criteria, which were described above.  
 
The primary outcome was the recurrence of any hypertensive disorder of pregnancy 
in the next subsequent pregnancy. Secondarily, we aimed at showing the recurrence 
of individual hypertensive syndromes. 
 
Statistical analysis 
Most studies focused on detailed data of the subsequent pregnancy, whereas some 
studies only registered details of the index pregnancy. To utilize the data as best as 
possible, we combined data of the index- and subsequent pregnancy for BMI, 
smoking, medical history and chronic hypertension. If for example BMI is recorded at 
the time of the second pregnancy, but not at the index pregnancy, then we copied 
this BMI information.  
Not all the dependent or independent variables have been registered in every 
database. Results are therefore accompanied with the number of cases in which the 
variable was registered (N). Proportions are presented as percentages of N, rather 
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than as percentages of the total population. For descriptive analysis we expressed 
continuous variables as mean with standard deviation (SD) or median with 
interquartile range (IQR), as appropriate. We decided not to use imputation, as the 
pattern of systematic missing values cannot be extrapolated between databases. 
 Differences in outcomes between the index and subsequent pregnancy were 
investigated using a random intercept random effects binomial regression model for 
dichotomous outcomes and using a random intercept random effects linear 
regression model for continuous outcomes. A random intercept was fitted per study 
to account for the fact that the baseline risk between studies may differ. Based on 
Akaike’s Information Criterion (AIC) the random effects model was compared to a 
fixed effects model and the model with the lowest AIC was used as the final model for 
analysis for that outcome. Heterogeneity across studies was assessed using the I2 
measure and the values were interpreted as follows: 0% indicates no observed 
heterogeneity; 25%, 50%, and 75% indicate low, moderate, and high heterogeneity, 
respectively (16). P values less than 0.05 were considered to indicate statistical 
significance.  
 We have performed 3 post hoc sensitivity analyses: in one we performed 
separate analysis for studies with less or more than 200 inclusions, in one we 
excluded retrospective studies and in one we excluded studies with high or unclear 
risk of bias.  
Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, 
USA) and R version 3.0.1 (The R Foundation for Statistical Computing). 
 
RESULTS 
Study selection: 
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Our search of Pubmed and Embase for eligible articles until August 2012 yielded 
2819 non-duplicate hits. After screening title and abstract, a total of 94 articles were 
included. Of these articles, six had to be excluded due to overlapping databases, 39 
due to failure to make contact, 14 due to unavailable data, two due to judgment of 
data as not useful by the authors and 11 authors decided not to share their data. 
Reasons for declining to share data included: no interest in participation, still in the 
publication process and a statement of ‘no permission to send data outside the 
national borders’. Eventually, the IPD of 22 articles (17-39) were included in this IPD 
meta-analysis (Figure 1). The combined database comprised a total of 99,415 
women.  
An overview of the study characteristics of the included studies can be seen in 
Table 1. The majority of women was included from three registry-based studies that 
lack demographic and clinical detail (31,32,38). Two authors of included registry-
based studies (21,38), were unable to provide the original data, but offered to 
perform a new data-extraction. They used the criteria from the initial study, creating 
an extended and more recent database. Eight prospective trials were included, 
investigating effects of aspirin (17,19,24,27,37), low-molecular-weight (LMW) heparin 
(25,27,37), vitamins (23,36) and close surveillance (37) on recurrence of 
hypertensive disease and maternal and fetal outcome. Quality characteristics of all 
included studies using the Newcastle Ottawa Scale (12) are shown in Figure 2.  
 
To test for selection bias in the process of inclusion of IPD, a meta-analysis of 
recurrence rates in literature was performed. We used the originally included 88 
articles (leaving out the overlapping datasets). Where available we used IPD (22 
articles). Another 24 articles had to be excluded because applicable recurrence rates 
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were not published. Of these articles, only IPD that did not reach publication would 
have been useful, for example in specific subgroups. Regarding gestational 
hypertensive disorders: 64 articles, encompassing in total 152,213 women with a 
hypertensive disorder of pregnancy, reported on 27,558 recurrences, resulting in a 
recurrence rate of 18.1% (95% CI: 17.9 – 18.3). The range of recurrence rates in the 
cohorts was: 6 to 83% (29). Recurrence rates of individual syndromes of HDP were 
not reported very consistently over studies. References of the 64 articles in this meta-
analysis are available as electronic supplementary material.  
 
The baseline characteristics of the 99,415 women included in the IPD are shown in 
Table 2. The occurrence of major maternal complications (like pulmonary edema or 
maternal death) was recorded too sporadic to report on. 
A hypertensive disorder of pregnancy (any type) recurred in 20,545 of 99,415 
women (20.7% 95%CI: 20.4 – 20.9). The Odds Ratio between this recurrence risk 
and the recurrence risk calculated with the 64 included articles is: 1.18 (95%CI: 1.15-
1.20, p: <.001). Recurrence manifested as PE in 13,725 women (N = 99,208, 13.8%, 
95%CI: 13.6 – 14.1) and GH in 6797 women (N= 79,169, 8.6% 95%CI: 8.4 – 8.8). 
HELLP complicated the HDP in 79 women (N= 39,301, 0.2%, 95%CI: 0.16 – 0.25). 
The delivery of a SGA child accompanied a hypertensive disorder in 1156 women 
(N= 34.359, 3.4%, 95%CI: 3.2 – 3.6). If we include non-hypertensive SGA as 
recurrence, SGA occurred in 4183 subsequent pregnancies (N= 34.359, 12%, 
95%CI: 11.8 – 12.5). The different numbers of women in which the specific 
hypertensive syndrome was recorded (N) cause these percentages to not add up to 
the 20.7% overall recurrence. Premature delivery accompanying the recurrent 
hypertensive disorder occurred < 37 weeks in 3316 women (N=99,415, 3.3% 95%CI: 
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3.2 – 3.5), < 34 weeks in 1224 women (N= 99,415, 1.2% 95%CI: 1.2 – 1.3) and < 28 
weeks in 179 (N= 99,415, 0.18% 95%CI: 0.16 – 0.22). Figure 3 gives a more detailed 
overview of recurrence of the separate syndromes of hypertensive disorders and 
effects of prematurity on recurrence according to hypertensive syndrome and 
gestational age at onset at the index pregnancy. 
 
Sensitivity analyses showed comparable recurrence rates when studies with unclear 
or high risk of bias were excluded from analysis and showed the same range of 
recurrence rates when discriminating studies by size and study design (data not 
shown). 
 
Subgroup analysis 
We compared recurrence amongst multiple and singleton pregnancies. Of the index 
pregnancies, 516 were multiple and 98.553 were singleton pregnancies. Recurrence 
occurred in 56 (10.9%) and 20.408 (20.7%), respectively (OR 0.53; 95% CI 0.40-
0.70, p-value: <.001). Furthermore, we performed a subgroup analysis based on the 
presence of thrombophilia and the association between LMW-heparin use and 
recurrence. The combined database included 206 women with and 296 without 
thrombophilia. A statistically significant interaction was present between 
thrombophilia and LMW-heparin use (p-value: 0.005). Stratified analysis in those with 
thrombophilia showed that 26 of 56 women (46%) who used prophylactic LMW-
heparin experienced recurrence of a hypertensive disorder of pregnancy, compared 
to 56 of 141 women (39.7%) who did not use LMW-heparin (OR 0.95; 95% CI 0.46-
2.0, p-value: 0.89). In those without thrombophilia 8 of 52 (15.4%) that used 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
14 
 
prophylactic LMW-heparin experienced recurrence, compared to 104 out of 244 
(42.6%) that did not use LMW-heparin (OR 0.44; 95% CI 0.13-1.5, p-value: 0.20) 
 
The clinical syndrome in the index and subsequent pregnancy 
To assess differences between the clinical hypertensive syndrome in the index and 
subsequent pregnancy in women with recurrence, we compared the variables as 
shown in Table 3. Heterogeneity was high for intravenous anticonvulsive medication, 
caesarean section, and premature delivery <34 and <37 weeks’ gestation, moderate 
for oral antihypertensive medication and premature delivery < 28 weeks’ gestation, 
low for maximum diastolic blood pressure, small for gestational age < p10, and 
absent for the other outcomes. The maximum diastolic blood pressure was on 
average lower in the subsequent pregnancy, proteinuria > 300mg / 24hours occurred 
less often and oral antihypertensive or intravenous anticonvulsive medication was 
necessary less frequently. The subsequent pregnancy was complicated less often by 
a caesarean section, delivery of a small for gestational age child, premature delivery 
and perinatal mortality. 
 Similar to the sensitivity analyses for recurrence rate, the analyses 
showed comparable associations between the index and subsequent pregnancy after 
excluding studies with unclear or high risk of bias and showed the same range of 
associations when discriminating studies by size and study design (data not shown). 
 
Chronic hypertension after pregnancy 
Chronic hypertension occurring after pregnancy was reported in 5 studies 
(28,29,30,34,35). After exclusion of chronic hypertension before pregnancy, we 
included 581 women, who were normotensive before pregnancy, who experienced a 
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hypertensive disease of pregnancy and in whom chronic hypertension after 
pregnancy was registered. Of these, 236 women (41%) had recurrence of a 
hypertensive disorder in the next pregnancy. Women with recurrence developed 
chronic hypertension more often than women without recurrence (28.4 versus 9.6%, 
OR 4.2 95% CI: 2.6 – 6.7).  
 
COMMENT: 
 
This IPD meta-analysis explored the recurrence risk and predictors for recurrence of 
hypertensive disorders of pregnancy. The creation of this large combined database 
produced an opportunity to calculate an overall recurrence rate of HDP and to 
explore the role of individual risk factors. Some of the bias introduced in single cohort 
studies based on patient selection criteria and methodology could be reduced. The 
diversity of inclusion criteria of the included databases reflects the diverse world 
population. 
 
Main findings 
The recurrence rate of a hypertensive disorder of pregnancy (any type) is 20.7% 
(95%CI: 20.4 – 20.9). Concomitant HELLP syndrome or delivery of a SGA child 
increases recurrence of HDP. Also, decreasing gestational age at delivery in the 
index pregnancy, both the chance of having recurrence and the chance to deliver 
prematurely again increase. Multiple pregnancy at the index pregnancy, as a risk 
factor for the occurrence of HDP, is protective for recurrence. Use of LMW heparin 
was not protective for recurrence in our data, but the numbers are too small to draw 
conclusions. If the hypertensive disorder recurred, it was in general milder, regarding 
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most of the investigated variables. Women who were normotensive before pregnancy 
and who experienced recurrence of a hypertensive disorder, had a four times 
increased risk of developing chronic hypertension after pregnancy. 
 
Strengths and weaknesses 
Undertaking this study was not without challenges. Study selection was impaired and 
prolonged by difficulties in contacting authors of the original articles. Eligible studies 
date back to the eighties, causing data to be lost, authors to be retired and accurate 
contact information to be absent. We were able to include 22 of the 88 (25%) eligible 
articles. Unfortunately, several important studies were not included. The inclusion 
rate is adequate compared to other published IPD meta-analyses with inclusion rates 
of 12-24% (41,42), one study included 6 of 10 eligible studies, adding up to an 
inclusion rate of 60% (42).  
The number of IPD in our study on the other hand, is much higher than in 
other IPDs, mostly containing several thousands of participants (40,41,42). The 
reason for this is our inclusion of nationwide registry based studies. Our combined 
database includes 99,415 women with a subsequent pregnancy, which is 69% of the 
143,659 women that could be included in our regular meta-analysis of the 88 eligible 
studies. In comparison with the meta-analysis of these 88 studies, the recurrence 
rates differ statistically: 20.7 versus 18.1%, OR: 1.18 (95%CI: 1.15-1.20, p: <.001). 
This suggests that some bias has occurred in the inclusion of data in our IPD. Thus, 
this IPD database may not be a completely representative cohort of the originally 
eligible studies, but it is close.  
 Another limitation of this study is the fact that we merged data that were 
obtained from very different study designs, settings and populations. This accounts 
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for the enormous range of recurrence rates between 6 and 83%. The upper bound of 
this range originates from a study with a very small and extreme high-risk population 
(29). It is unsurprising that heterogeneity across studies, assessed using the I2 
measure, was high for some of our results. The missing data that inevitably originate 
from merging databases challenged the statistical analysis. One of the methods that 
we used to overcome the problem of missing data is the merging of information on 
BMI, smoking, medical history and chronic hypertension between the two 
consecutive pregnancies. Although these characteristics can vary, we do think that 
on average, it gives a good indication of risk profile for the individual woman.  
 Furthermore, we included prophylactic trials in this IPD meta-analysis: 7 
randomized controlled trials, which investigated the effect of aspirin (17,19,24) versus 
placebo, vitamins versus placebo (23,36), LMW-heparin plus aspirin versus aspirin 
alone (27) or LMW-heparin in thrombophilic women versus no treatment in non-
thrombophilic women (37). The inclusion of these studies might be problematic when 
the treatments investigated in the different studies were effective in the reduction of 
hypertensive disorder recurrence. Two trials found a significant treatment effect. One 
trial found a significant reduction of recurrence in those treated with LMW-heparin 
plus aspirin compared with aspirin alone (27), but the numbers were very small (1 
and 7 women experienced preeclampsia in the next pregnancy). The same applies 
for a trial reporting a significant effect of vitamin use compared to placebo (23). In 
addition, another vitamins trial shows conflicting results (36). Given the small sample 
sizes of the trials with a significant treatment effect and given these unclear relations 
to the recurrence of HDP, we do not expect that the inclusion of these studies 
hampers the generalizability of the results of this IPD meta-analysis in any way.  
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Variables that were infrequently registered, limited the analyses of the data. The 
percentages shown in Table 2 could therefore be difficult to interpret. HELLP 
syndrome was only recorded present in 512 women (0.5% of all included women) 
and SGA accompanied a HDP in 6448 cases (7%). This is unfortunate, as they are 
parts of the placental syndrome. The same applies for the inclusion of multiple 
pregnancy in the index pregnancy of 0.5%, being an exclusion criterion in some 
included studies. The presence of thrombophilia also requires an explanation. If 
registered, thrombophilia was present in 41%. The inclusion of studies with 
thrombophilia as one of the inclusion criteria resulted in this high percentage. We do 
not think this will act as bias, since it is only documented in 0.5% of the total cohort.  
 
Another problem is reporting bias. Eclampsia was reported quite often (8% in 26.665 
women in whom this complication was registered) in the index pregnancy. It is 
understandable that if eclampsia occurred, it is more likely to be registered than when  
it did not occur. 
 
Sensitivity analysis in which we discriminated studies by study design and size 
showed some discordant results. This was mainly due to loss of power: the analyses 
of small studies and prospective studies separately comprised 972 and 1955 of the 
915.415 inclusions respectively (1 and 2%). In contrast, the overall analysis was 
mainly dominated by three large retrospective studies (31,32,38). Also, the results 
were difficult to interpret as most prospective studies did not register clinical details of 
the index pregnancy. The sensitivity analysis that included only low risk of bias 
studies had results that were comparable to the overall results, mainly because only 
3 small studies were excluded from analysis (26,27,29). 
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Counseling 
Counseling couples about the chance of recurrence is important. This IPD meta-
analysis did not include women, who refrained from a subsequent pregnancy. Three 
included databases contained information on the reason for not engaging in a 
subsequent pregnancy (30,34,35). Of 471 women, 140 (29%) refrained from a next 
pregnancy due to high perceived risk. This does not comply with the 21% recurrence 
risk and the fact that HDP recur in a milder form. The knowledge from this IPD meta-
analysis can be used in counseling in the future. 
  
In conclusion, interpretation of previous data of individual cohort studies was 
hampered by many sources of bias. IPD meta-analysis is a methodologically and 
logistically challenging approach. However, despite all the challenges and limitations 
stated above, the results are based on the largest database regarding recurrence of 
HDP so far. The opportunities of aggregated datasets are of paramount importance, 
because they allow the calculation of overall recurrence rates and also identify more 
accurately the role of individual risk factors on an individual level. The present IPD 
meta-analysis helped to create knowledge that can comprehensively be included in 
the counseling of couples after experiencing hypertensive disease of pregnancy. 
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Figure 1:  
Inclusion of articles 
 
 
Figure 2: 
Risk of bias graph 
 
Quality characteristics of all included studies, evaluated with the Newcastle Ottawa 
Scale for cohort studies. The item “selection of the on exposed cohort” was not 
relevant in this IPD and was therefore indicated as ‘low risk’ in all studies. 
 
 
Figure 3A. Recurrence rates of the individual hypertensive syndromes of the 99,415 
included patients according to the hypertensive syndrome at the index pregnancy 
 
Figure 3B. Recurrence rates of the individual hypertensive syndromes of the 99,415 
included patients according to the gestational age at onset (or diagnosis) of the 
hypertensive syndrome at the index pregnancy 
 
 
Table 1:  
Overview of study characteristics of the included studies 
 
 
Table 2: 
Baseline clinical characteristics and index pregnancy parameters of the 99,415 
included patients 
 
 
Table 3: 
Differences in the clinical hypertensive syndrome between the index and subsequent 
pregnancy in recurrent disease 
 
 
Electronic supplementary material:  
References of the 60 articles included in the meta-analysis preceding the IPD meta-
analyses 
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Table 1- Overview of study characteristics of the included studies   
 
Study and 
Year Country Inclusion criteria Exclusion criteria Study design 
Therapeutic 
trial 
Total 
women 
original 
study  
Total 
includable 
women*  
 
(recurrence 
rate) 
Beroyz 199417 United 
Kingdom 
- Former PE  
- Former FGR 
- Chronic hypertension 
- Renal disease 
- Signs of PE or FGR in 
current pregnancy 
- Bleeding disorders 
- Asthma 
- Allergy to aspirin 
Randomized 
controlled trial 
Aspirin vs 
placebo 
9364 156 
 
 
(59%) 
Brown 200718 Australia - Former PE  
- Former GH 
- Chronic hypertension 
- Essential hypertension 
and superimposed PE 
- None reported Retrospective 
cohort study  
- 1354 765 
 
 
(32%) 
Byaruhanga 
199819 
South-
Africa 
- Former PE  
- Former GH 
- Chronic hypertension 
- History of 
hypersensitivity to 
aspirin, peptic ulcer, 
bleeding disorders or 
chronic pulmonary 
disease 
- Use of NSAID’s 
- Development of PE prior 
to trial entry 
Randomized 
controlled trial 
Aspirin vs 
placebo 
250 213 
 
 
(15%) 
Cameroni 
201120 
Italy - Former PE  
- Former FGR 
- Former placental 
abruption 
- Former stillbirth 
- Chronic hypertension 
- Retrospective 
cohort study 
 218 173 
 
 
(10%) 
Campbell 1985 
and 201021,22  
United 
Kingdom 
- Total population of 
Aberdeen Maternity 
and Neonatal Data 
Bank 
- Retrospective 
cohort study 
- 38130 7,725 
Extended 
extraction** 
(26%) 
Chappell 
199923 
United 
Kingdom 
- Former PE < 37wks 
- Former HELLP or 
eclampsia at any GA 
- Abnormal uterine- 
artery doppler 
waveform in 
pregnancy 
- Heparin or warfarin 
treatment 
- Fetal abnomalities 
- Multiple pregnancy 
Randomized 
controlled trial 
Antioxidants 
(Vit C and E) 
vs placebo 
283 56 
 
 
(50%) 
Chiaffarino 
200424 
Italy - Former severe PE or 
eclampsia 
- Former FGR  
- Former intrauterine 
foetal death 
- Chronic disease other 
than hypertension, renal 
disease or diabetes 
- Allergy to aspirin  
- Fetal malformations 
- current twin pregnancy 
Randomized 
controlled trial 
Aspirin vs no 
treatment 
40 15 
 
 
(47%) 
Conserva 
201225 
Italy - Former PE  
- Former HELLP  
- Former GH 
- Former FGR 
- Former placental 
abruption 
- Former FGR and 
stillbirth  
- acquired thrombophilia 
- clinical immune disease 
- treatment with LMWH in 
previous pregnancy 
- congenital fetal anomaly 
- non Caucasian ethnicity 
Prophylactic 
trial 
Enoxaparine 128 53 
 
 
(11%) 
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Facchinetti 
200926 
Italy - Former PE in singleton 
pregnancy 
- A complete evaluation 
for thrombophilia. 
- Current singleton 
pregnancy 
- History of 
thromboembolic 
diseases 
- Renal and/or 
cardiovascular disorder 
- Systemic lupus 
erythematosus  
- Diabetes 
- Any ethnic group other 
than white 
Prospective 
cohort study 
- 172 172 
 
 
(34%) 
Ferrazzani 
200627 
Italy - Previous severe 
preterm PE with 
associated FGR 
- Former HELLP 
syndrome 
Prophylactic 
trial 
Aspirin vs 
aspirin and 
heparin 
68 54 
 
(15%) 
Figueiro-Filho 
201228 
Brasil - Previous severe PE 
with one of the 
following: 
- hospitalization < 
32wks 
- imminent eclampsia 
- eclampsia 
- HELLP syndrome 
- systemic laboratory 
tests 
- preterm birth < 34 wks 
- admission of newborns 
in NICU 
- fetal loss 
- fetal growth restriction 
- oligohydramnia 
- abnormal uterine or 
umbilical artery 
doppler   
- Chronic hypertension 
- Systemic lupus 
erythematosus 
- Thrombophilia  
 
Prospective 
cohort study 
- 113 67 
 
 
(50%) 
Gaugler-
Senden 200829 
The 
Netherland
s 
- Former severe PE < 
24wks 
- Retrospective 
cohort study  
- 20 18 
 
(83%) 
Langenveld 
201130 
The 
Netherland
s 
- Former PE, GH or 
HELLP < 34wks in 
singleton pregnancy 
- Fetal abnormalities Retrospective 
cohort study  
- 380 211 
 
(55%) 
Lykke 200931 Denmark - All women with two  
singleton deliveries in 
the National Patient 
Registry  
- cardiovascular diagnosis  
- diabetes  
- women who died or 
emigrated within 3 
months of the second 
delivery 
Retrospective 
cohort study  
- 536,419 26,939  
 
 
(20%) 
Mbah 201232 United 
States of 
America 
- All women with two 
pregnancies registered 
in the Missouri 
maternally linked 
cohort database 1989 
– 2005 
- Retrospective 
cohort study 
- 166712 23,390 
 
 
(17%)  
Napolitano 
201133 
United 
Kingdom 
- all nulliparous women 
- parous women with 
former PE or FGR 
- concurrent maternal 
medical conditions 
- >7 years since last 
pregnancy 
- Miscarriage < 14 wks 
- Fetal chromosomal or 
structural abnormalities 
Prospective 
cohort study 
- 6221 273 
 
 
(26%) 
van Oostwaard 
201234 
The 
Netherland
s 
- Former PE, GH, 
HELLP or FGR 34 - 37 
wks  
- Fetal abnormalities Retrospective 
cohort study 
- 425 189 
 
(34%) 
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van Oostwaard 
201435 
The 
Netherland
s 
- Former PE, GH or 
HELLP > 37 wks 
- Fetal abnormalities Retrospective 
cohort study 
- 638 312 
 
(41%) 
Poston 200636 United 
Kingdom 
- Former PE < 37wks 
- Former HELLP or 
eclampsia at any GA 
- Other risk factors for 
hypertensive disease 
(Essential 
hypertension, 
Diabetes, renal 
disease, 
Antiphospholipid 
syndrome, abnormal 
uterine- artery doppler 
waveform in 
pregnancy or BMI>30) 
- No informed consent 
- Warfarin treatment  
- Using vitamins before 
trial 
Randomized 
controlled trial 
Vitamins (Vit 
C and E) vs 
placebo 
2404 556 
 
 
(29%) 
Salim 200837 Isreal - IUFD 
- SGA 
- severe PE or  
- placental abruption  
- in any former 
pregnancy > 23wks 
Former pregnancy with: 
- multiple gestation 
- major congenital or 
chromosomal anomalies 
- fetal infection / 
chorioamnionitis 
- hydrops  
- diabetes mellitus 
Prospective 
cohort study 
- Close 
surveillance 
- LMW 
heparin if 
thrombophili
a  
- Aspirin 
added if 
antiphospho-
lipid 
antibodies 
97 19 
 
 
(16%) 
Trogstad 
200438 
Norway - All women with two  
singleton deliveries in 
the Medical Birth 
Registry 
- And preeclampsia in 
the first pregnancy 
- Multiple gestation (triplet 
or more) in the first 
pregnancy 
- Multiple gestation in the 
subsequent pregnancy 
(2 or more) 
Retrospective 
cohort study 
- 20,285 
 
37,738 
Extended 
extraction** 
 
(22%) 
Zhang 200139 United 
States of 
America 
- Women attending the 
prenatal care unit 
during inclusion period 
- And two consecutive 
pregnancies  
- Prospective 
cohort study 
- 1641 321 
 
 
(24%) 
Total:       99,415 
 
* Includable women: women with hypertensive disease (PE, GH, HELLP) in a former pregnancy, with a 
subsequent pregnancy, excluding control groups and cases without hypertensive complications in former 
pregnancies. 
** New extended data extraction from the registry on behalf of this IPD, using the same inclusion criteria from the 
original cohort 
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Demographic  N*  
% of total 
99,415 References 
Age at index pregnancy (years)  97,832  25 (SD: 5)   17 18 21 22 24  27 29 30 31 32  
34 35 38 39 
Smoking  27,304  5654 (21%) 6% 17 18 21 22 26 29  30 31 34 35 36 39 
Ethnicity 
- European 
- Caribbean 
- Asian 
- Sub-Saharan Africa 
- Middle East 
 25,807 
20,785 (81%) 
 113 (0.4%) 
 228 (0.9%) 
 4545 (5%) 
 19 (0.1%) 
21% 
0.1% 
0.2% 
5%% 
0% 
17 20 23 25 26  
27 28 29 30 32  
33 34 35 36 39 
Body mass index, BMI (kg/m2)  32,544 25 (IQR: 22 - 29)   21 22 23 25 29 30  32 33 34 35 36 39 
Chronic hypertension before 
pregnancy  26,879  2032 (8%) 2.0% 
17 20 23 25 26  
27 28 29 30 32  
34 35 36 38 39 
Thrombophilia  502  206 (41%) 0.2% 25 26 28 30  34 35 37 
History of 
disease  
 
- Diabetes Mellitus 
- Coronary disease 
- Kidney disease 
 90,749 
 51,387 
 25,004 
 1342 (1.5%) 
 167 (0.3%) 
 121 (0.5%) 
1,3% 
0.2% 
0.1% 
17 18 20 23 24 26 
27 28 29 30 32 33 
34 35 36 37 38 39 
Pregnancy characteristics of index pregnancy 
Nulliparous   72,412 65,243 (90%) 66% 17 18 19 20 21 22 23 24  25 26 27 28 29 30 32 33 
34 35 36 37 38 39 
Multiple pregnancy  99,069  516 (0.5%) 0.5% 17 18 19 20 21 22  23 24 25 26 28 29 30  
32 34 35 36 38 39 
Gestational hypertension†  99,400 23,970 (24%) 24% 
17 18 19 20 21 22  
23 24 25 26 27 28  
28 30 31 32 33 34  
35 36 37 38 39 (all) 
Preeclampsia†  99,202 75,172 (76%) 76% 
17 18 19 20 21 22  
23 24 25 26 27 28  
28 30 31 32 33 34  
35 36 37 38 39 (all) 
Eclampsia†  26,665  2087 (8%) 2.1% 17 18 25 28 29  30 32 34 35 38 
HELLP syndrome†  40,236  512 (1.3%) 0.5% 17 18 20 25 27 28  29 30 34 35 36 38  
Placenta Abruption 51.803  1221 (2.4%) 1.2% 20 25 28 30 31  32 34 35 37 39  
Maximum blood 
pressure (mmHg) 
- Systolic 
- Diastolic 
 632 
1028 
 161 (SD: 21)  
 103 (SD: 11) 
0.2% 
0.1% 29 30 34 35 39 
Use of 
medication 
- oral antihypertensive 
- iv antihypertensive 
- iv anticonvulsive 
 1446 
 687 
 1472 
 738 (51%) 
 141 (21%) 
 219 (15%) 
0.7% 
0.1% 
0.2% 
18 29 30 34 35 
Gestational age at delivery (weeks)  94,178 39 (SD: 20 days)  18 21 22 25 26  27 29 30 31 32  
34 35 37 38 39 
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Birth weight (grams)  97,694 3185 (SD: 761)  18 21 22 25 26  27 29 30 31 32  
34 35 37 38 39 
Small for Gestational Age†  35,109  6448 (18%) 6.4% 17 18 20 21 22 23 24  25 27 28 29 30 32  
33 34 35 37 38 39 
Premature 
delivery 
< 28 weeks 
< 34 weeks 
< 37 weeks 
 94,197 
94,353 
94,965 
 739 (0.8%) 
 5363 (5.7%) 
 14521 (15%) 
0.7% 
5.4% 
15% 
17 18 21 22 23 25 
26 27 29 30 31 32 
34 35 37 38 39 
Caesarean Section  93,948 28,081 (30%) 28% 18 21 22 25 27 28 30  31 32 34 35 37 38 
NICU admission neonate 5117  1157 (22%) 1.2% 18 38 
Perinatal mortality  98,078  1608 (1.6%) 1.6% 17 18 20 21 22 24  25 27 29 30 31 32  
34 35 37 38 39 
Characteristics at the subsequent pregnancy 
Birth interval (months)  59,754  41 (SD: 25)  18 21 22 29 30 
 31 32 34 35 39 
Change of partner  7344  668 (9%) 0.7% 20 21 22 23 35 39 
Use of 
prophylaxis   
- Aspirin 
- LMW Heparin 
- Both 
 5663 
 1962 
 1909 
 737  (13%) 
 153  (8%) 
 60  (3%) 
0.7% 
0.2% 
 0.1% 
17 19 20 21 22 
23 24 26 27 28 
30 34 35 36 37 
Continuous data are presented as means (SD); age, BMI and gestational age in median (IQR) 
Proportions are shown as n (% of N) 
* Number of women with available information 
† Percentages sum up to more than 100% because of overlapping of disorders 
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Table 3. Differences in the clinical hypertensive syndrome between the index and subsequent 
pregnancy in recurrent disease  
 
 
Women with recurrence  
N= 20,545      N* 
Index  
Pregnancy 
Subsequent 
pregnancy P I
2
 (%) References 
Max systolic BP (mmHg)** 194  165 (19)  153  (17) 0.055 0 17 19 27 29  30 34 35 36  
Max diastolic BP (mmHg)** 331  107  (11)  100  (8.9) <.001 25 29 30 34 35 39 
Proteinuria > 300mg/24h  119  82  (69%)  58  (49%) 0.011 0 18 29 27 30 34 35 
Thrombocytopenia < 100 *109/L 162  37  (23%)  18  (11%) 0.24 0 18 29 30 34 35 
Use of 
medication 
- oral antihypertensive 
- iv antihypertensive 
- iv anticonvulsive 
504 
263 
508 
 295  (59%) 
 67  (26%) 
 82  (16%) 
 237  (47%) 
 27  (10%) 
 31  (6%) 
0.002 
0.12 
<.001 
71 
0 
72 
17 18 19 23 25 28  
29 30 34 35 36 
Hospital days*** 154  5  (2-11)  3  (1-5) 0.17 0 34 35 
Caesarean section 18,488  6195  (34%)  6423  (35%) <.001 99 17 18 19 20 21 22  25 26 28 29 30 31  
32 34 35 37 38 
Small for gestational age < p10 6,542  996  (15%)  841  (13%) <.001 45 17 18 20 21 22 23  25 27 28 29 30 32  
33 34 35 37 38 39 
Perinatal mortality 20,111  466  (2.3%)  256  (1.3%) <.001 0 17 18 20 21 22 24  25 27 29 30 31 32  
33 34 35 37 38 39 
Premature delivery 
< 28 weeks 
< 34 weeks 
< 37 weeks 
18,638 
18,735 
18,925 
 267  (1.4%) 
 1868  (10%) 
 4312  (23%) 
 155  (0.8%) 
 1106  (5.9%) 
 3125  (17%) 
<.001 
<.001 
<.001 
54 
76 
93 
18 21 22 25 26  
27 29 30 31 32  
34 35 37 38 39 
* Number of women with available information for both of the pregnancies 
** Data are presented as means (SD). 
***Data are presented as median (IQR). 
Significant differences are indicated in bold 
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Figure 1. Inclusion of articles 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Pubmed: 
Hits 948 
Embase: 
Hits 2673 
Duplications: 802 
Total: 
2819 articles 
Selection by reviewers: 
94 articles 
Overlapping data: 6 
Total included: 
22 articles 
Failed contact: 39 
Data lost: 14 
Data not useful: 2 
Not sharing: 11 
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ACCEPTED MANUSCRIPTFigure 3A. Recurrence rates of the individual hypertensive syndromes of the 99,415 included patients according to the hypertensive syndrome at the index pregnancy 
 
Data are shown as frequencies with percentages to the number of cases in which both variables were registered.  
Number of women with specific hypertensive disorder at the index pregnancy: Any type 99.241; PE 75.172; GH 
23.970; HELLP 512; SGA 6448 
 
Figure 3B. Recurrence rates of the individual hypertensive syndromes of the 99,415 included 
patients according to the gestational age at onset (or diagnosis) of the hypertensive syndrome 
at the index pregnancy 
** n = Number of women with specific hypertensive disorder included in the database 
Data are shown as frequencies with percentages to the
 number of cases in which both variables were registered (close 
*   N = Number of women with available information
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Data are shown as frequencies with percentages to the number of cases in which both variables were registered.  
Number of women with specific Gestational Age at the index pregnancy: Any GA 99.415; <37 wks 14.512; <34 
wks 5354; <28 wks 730 
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